熱門資訊> 正文

Immunovant GAAP每股收益为-0.71美元

2025-08-11 19:21

Immunovant press release (NASDAQ:IMVT): Q1 GAAP EPS of -$0.71 misses by $0.02.
As of June 30, 2025, Immunovant’s cash and cash equivalents totaled approximately $598.9 million, providing runway for announced indications through GD readout expected in 2027.

More on Immunovant

Immunovant: Navigating The Complexities Of The FcRn Landscape (Downgrade)
Seeking Alpha’s Quant Rating on Immunovant
Historical earnings data for Immunovant
Financial information for Immunovant

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。